- Home
- SLDB vs TRVI Comparison
SLDB vs TRVI Comparison
Compare SLDB & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLDB
- TRVI
- Stock Information
- Founded
- SLDB 2013
- TRVI 2011
- Country
- SLDB United States
- TRVI United States
- Employees
- SLDB N/A
- TRVI N/A
- Industry
- SLDB Biotechnology: Biological Products (No Diagnostic Substances)
- TRVI Biotechnology: Pharmaceutical Preparations
- Sector
- SLDB Health Care
- TRVI Health Care
- Exchange
- SLDB Nasdaq
- TRVI Nasdaq
- Market Cap
- SLDB 227.3M
- TRVI 211.4M
- IPO Year
- SLDB 2018
- TRVI 2019
- Fundamental
- Price
- SLDB $4.03
- TRVI $4.15
- Analyst Decision
- SLDB Strong Buy
- TRVI Strong Buy
- Analyst Count
- SLDB 11
- TRVI 8
- Target Price
- SLDB $17.91
- TRVI $9.31
- AVG Volume (30 Days)
- SLDB 279.8K
- TRVI 4.1M
- Earning Date
- SLDB 11-06-2024
- TRVI 11-06-2024
- Dividend Yield
- SLDB N/A
- TRVI N/A
- EPS Growth
- SLDB N/A
- TRVI N/A
- EPS
- SLDB N/A
- TRVI N/A
- Revenue
- SLDB N/A
- TRVI N/A
- Revenue This Year
- SLDB N/A
- TRVI N/A
- Revenue Next Year
- SLDB N/A
- TRVI N/A
- P/E Ratio
- SLDB N/A
- TRVI N/A
- Revenue Growth
- SLDB N/A
- TRVI N/A
- 52 Week Low
- SLDB $4.00
- TRVI $1.26
- 52 Week High
- SLDB $15.05
- TRVI $4.68
- Technical
- Relative Strength Index (RSI)
- SLDB 29.01
- TRVI 67.54
- Support Level
- SLDB $4.82
- TRVI $2.36
- Resistance Level
- SLDB $5.40
- TRVI $4.60
- Average True Range (ATR)
- SLDB 0.34
- TRVI 0.35
- MACD
- SLDB -0.08
- TRVI 0.20
- Stochastic Oscillator
- SLDB 1.63
- TRVI 77.32
About SLDB Solid Biosciences Inc.
Solid Biosciences Inc is a life science company. It is engaged in the manufacturing of specialty and generic drugs. The company is involved in curing Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. The company's pipeline products are the SB-001 and solid suit. The Company's singular focus is on developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases. The company has categorized its programs into corrective therapies, disease-modifying therapies, and assistive devices.
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.